{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:06:45Z","timestamp":1793898405644,"version":"4.8.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001030","name":"National Heart Foundation of Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","award":["03-006-2022-0052"],"award-info":[{"award-number":["03-006-2022-0052"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.rpth.2026.106627","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:28:44Z","timestamp":1777602524000},"page":"106627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intrinsic activated thrombin generation for treatment efficacy and monitoring of octocog alfa and emicizumab in severe hemophilia A"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0405-2459","authenticated-orcid":false,"given":"Emma H.","family":"Urlings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floor C.J.I.","family":"Heubel-Moenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"van Oerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave L.S.","family":"Hellenbrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola E.J.","family":"van der Meijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman M.","family":"Hackeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo ten","family":"Cate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdolna","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne M.C.","family":"Henskens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri M.H.","family":"Spronk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.106627_bib1","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"Lenting","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106627_bib2","first-page":"223","article-title":"Emicizumab for the treatment of haemophilia A: a narrative review","volume":"17","author":"Franchini","year":"2019","journal-title":"Blood Transfus"},{"key":"10.1016\/j.rpth.2026.106627_bib3","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1055\/a-1665-6232","article-title":"An update on laboratory diagnostics in haemophilia A and B","volume":"42","author":"M\u00fcller","year":"2022","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.rpth.2026.106627_bib4","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s40262-021-01042-w","article-title":"Pharmacokinetics and associated efficacy of emicizumab in humans: a systematic review","volume":"60","author":"Donners","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.rpth.2026.106627_bib5","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.jtha.2025.10.029","article-title":"Pharmacokinetic-guided dose reduction of emicizumab in congenital hemophilia A: interim analysis of the DosEmi study","volume":"24","author":"van der Zwet","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106627_bib6","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/hae.13990","article-title":"Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors","volume":"26","author":"Bowyer","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106627_bib7","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1373\/clinchem.2015.248625","article-title":"Thrombin generation assay and its application in the clinical laboratory","volume":"62","author":"Tripodi","year":"2016","journal-title":"Clin Chem"},{"key":"10.1016\/j.rpth.2026.106627_bib8","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1111\/jth.12012","article-title":"Preanalytic variables of thrombin generation: towards a standard procedure and validation of the method","volume":"10","author":"Loeffen","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106627_bib9","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/jth.12474","article-title":"Anti-factor IXa\/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation","volume":"12","author":"Muto","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106627_bib10","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1111\/jth.13134","article-title":"Thrombin generation assay using factor XIa to measure factors VIII and IX and their glycoPEGylated derivatives is robust and sensitive","volume":"13","author":"Waters","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106627_bib11","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2018-99-111675","article-title":"The relationship between thrombin generation assay and FVIII levels in patients with mild to moderate haemophilia (A)","volume":"132","author":"Luo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106627_bib12","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1182\/blood-2019-130875","article-title":"Novel thermostable inhibitor of contact activation TICA effectively blocks contact activation in low tissue factor thrombin generation","volume":"134","author":"Van De Berg","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106627_bib13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1182\/blood-2020-136536","article-title":"Longitudinal assessment of thrombin generation in patients with hemophilia receiving fitusiran prophylaxis: phase II study results","volume":"136","author":"N\u00e9grier","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106627_bib14","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/S0140-6736(23)00514-7","article-title":"Fitusiran in haemophilia: a breakthrough drug with many unknowns","volume":"401","author":"Peyvandi","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2026.106627_bib15","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1055\/a-2101-7961","article-title":"Sensitive measurement of clinically relevant factor VIII levels in thrombin generation assays requires presence of factor XIa","volume":"123","author":"van de Berg","year":"2023","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106627_bib16","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1160\/TH04-10-0706","article-title":"Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B","volume":"93","author":"Dargaud","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106627_bib17","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1111\/jth.15106","article-title":"Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: combining thrombin and plasmin generation","volume":"18","author":"Valke","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106627_bib18","article-title":"No correlation between thrombin generation and emicizumab levels: implications for monitoring emicizumab therapy","volume":"9","author":"van der Zwet","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106627_bib19","article-title":"The implication of new developments in hemophilia treatment on its laboratory evaluation","volume":"14","author":"Anandani","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.rpth.2026.106627_bib20","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/bloodadvances.2019000849","article-title":"Laboratory monitoring of hemophilia A treatments: new challenges","volume":"4","author":"Lenting","year":"2020","journal-title":"Blood Adv"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926032851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926032851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:24:46Z","timestamp":1784546686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926032851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2475037926032851"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106627","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intrinsic activated thrombin generation for treatment efficacy and monitoring of octocog alfa and emicizumab in severe hemophilia A","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106627","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"106627"}}